Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors

BACKGROUND: Colorectal cancer (CRC) is the second most common cause of cancer-related mortality worldwide with one in every five patients diagnosed with metastatic CRC (mCRC). In mCRC cases, the 5-year survival rate remains at approximately 14%, reflecting the lack of effectiveness of currently avai...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Kennedy, Susan A., Morrissey, Maria E., Dunne, Margaret R., O’Connell, Fiona, Butler, Clare T., Cathcart, Mary-Clare, Buckley, Amy M., Mehigan, Brian J., Larkin, John O., McCormick, Paul, Kennedy, Breandán N., O’Sullivan, Jacintha
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7532092/
https://ncbi.nlm.nih.gov/pubmed/33008336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07430-y
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia